These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract.
    Author: Ilhan-Mutlu A, Preusser M, Schoppmann SF, Asari R, Ba-Ssalamah A, Schwameis K, Pluschnig U, Birner P, Püspök A, Zacherl J, Hejna M.
    Journal: Anticancer Res; 2013 Aug; 33(8):3455-9. PubMed ID: 23898119.
    Abstract:
    BACKGROUND: The efficacy of triple-drug combination regimens such as docetaxel, cisplatin and 5-fluorouracil (DCF), and epirubicin, oxaliplatin and capecitabine (EOX), is superior to standard cisplatin/5-fluorouracil in patients with upper gastrointestinal adenocarcinoma. In this analysis, we compare DCF and EOX regarding toxicity and efficacy. PATIENTS AND METHODS: Patients received either intravenous docetaxel at 75 mg/m(2), cisplatin at 75 mg/m(2), both given on day 1, and 5-fluorouracil at 750 mg/m(2), on days 1 to 5, or epirubicin at 50 mg/m(2) i.v. on day 1, oxaliplatin at 130 mg/m(2) i.v. on day 1 and capecitabine at a twice-daily dose of 1000 mg/m(2) p.o. for two weeks; both regimens were repeated every three weeks. RESULTS: Response rates for DCF and EOX were 28% and 10%, time-to-progression was 26 and 20 weeks, and overall survival were 54 and 52 weeks, respectively. CONCLUSION: We conclude that further investigations within comparative prospective clinical trials of these regimens are warranted.
    [Abstract] [Full Text] [Related] [New Search]